熱門資訊> 正文
Barinthus Biotherapeutics GAAP每股收益为-0.52美元
2025-08-07 23:13
- Barinthus Biotherapeutics press release (NASDAQ:BRNS): Q2 GAAP EPS of -$0.52.
- As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8 million, compared to $100.6 million as of March 31, 2025.
More on Barinthus Biotherapeutics
- Seeking Alpha’s Quant Rating on Barinthus Biotherapeutics
- Historical earnings data for Barinthus Biotherapeutics
- Financial information for Barinthus Biotherapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
